Although the optimal duration of concomitant ADT for intermediate-risk PCa when combined with 125I-TPPB remains unknown until the results from SHIP0804 study [5] are available, it may be possible to minimize the duration of ADT and its related toxicities for patients who achieve a rapid fall in testosterone and PSA after starting neoadjuvant ADT. This evidence concerns the gene KLK3 and posterior cortical atrophy.